Major Hip and Knee Joint Replacement DRG 469 | DRG Reimbursement

Summary & Overview

Major Hip and Knee Joint Replacement or Reattachment: Inpatient Reimbursement Overview

DRG 469 pertains to major hip and knee joint replacement or reattachment of the lower extremity with a Major Complication or Comorbidity, and includes total ankle replacement when classified at this severity level. This Diagnosis-Related Group matters for inpatient reimbursement because it reflects higher resource consumption and drives increased Medicare Severity Diagnosis-Related Group payments for complex orthopedic hospitalizations.

DRG Major Hip and Knee Joint Replacement or Reattachment of Lower Extremity with MCC or Total Ankle ReplacementDRG 469Diagnosis-Related GroupInpatient ReimbursementMedicareOrthopedicsJoint ReplacementTotal Ankle ReplacementHip ReplacementKnee Replacement

DRG 469 Overview

DRG 469 covers major hip and knee joint replacement procedures and reattachment of the lower extremity when a Major Complication or Comorbidity is present, and includes total ankle replacement cases that meet similar resource intensity. This Diagnosis-Related Group groups inpatient stays by high-cost orthopedic procedures with significant perioperative complexity and comorbid conditions. It matters for Medicare payment because cases assigned here drive higher Medicare Severity Diagnosis-Related Group reimbursements to reflect increased resource use, longer lengths of stay, and added care needs. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and associated payment.

National Payment Rates

Across commercial payers, negotiated rates for DRG 469 range widely from about $27K (UHC) up to $110K (Anthem), with most payers clustering between roughly $41K and $50K; the widest spread is between UHC at $27K and Anthem at $110K. See the table and chart below for payer-level percentiles and distributions including BCBS, Aetna, Cigna, Anthem, and UHC.

Mean Rates by Payer — National — DRG 469

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($28.5k), average submitted covered charges ($138.8k), average Medicare payment amount ($24.8k), and total discharges (5.7k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

DRG 469 reimbursement in Alaska spans from a low floor of $7.5K (Anthem and BCBS p25/min) up to a high of $130K (Cigna max), with payer medians clustering at $47K for Anthem/BCBS and $72K for Cigna. The most notable deviation from national averages is Cigna’s elevated median and maximum, which exceed typical national medians, while Anthem and BCBS present an unusually wide range that includes very low values. See the table and chart below for detailed distributions by payer.

Key Insights for Alaska

Highest payer: Cigna (median $72K; max $130K) — notably above national medians for multiple payers, indicating a higher ceiling in AK.
Lowest payers: Anthem and BCBS (median $47K; min $7.5K) — both show a wide low-end floor down to $7.5K, which is meaningfully lower than typical national p25 values.
Meaningful deviation: Cigna’s median and max are substantially higher than national medians, while Anthem/BCBS exhibit a much wider range with a very low p25 compared with national benchmarks.

Clinical Trials

Perioperative optimization and complication-prevention trials: These studies evaluate interventions delivered in the immediate preoperative and inpatient periods—such as enhanced prehabilitation protocols, multimodal pain control regimens, thromboprophylaxis strategies, and infection-prevention bundles—for patients undergoing major hip or knee arthroplasty or lower-extremity reattachment with major comorbidities (MCC). The population typically includes older adults with cardiovascular disease, diabetes, obesity, or renal impairment who are at higher risk for in-hospital complications and prolonged length of stay. Results matter to providers and payers because reducing perioperative complications and length of stay can directly impact resource utilization, readmission rates, and the total cost of the episode of care for this high-acuity DRG.
Comparative effectiveness and device-outcome studies at index hospitalization: These trials compare surgical techniques, fixation methods, implant types (including total ankle replacements when appropriate), or intraoperative strategies in patients receiving major hip/knee replacement or reattachment, often stratified by severity and comorbidity burden. The research questions focus on short-term outcomes such as intraoperative blood loss, need for transfusion, immediate postoperative mobility, prosthesis alignment, and early complication rates in the inpatient period. Findings inform surgeon decision-making about approaches that balance clinical benefit and perioperative resource demands, which is critical for DRG-based reimbursement and for hospitals optimizing care pathways for patients with complex medical backgrounds.
Post-discharge outcomes, rehabilitation, and bundle-of-care trials: These studies examine post-acute care pathways, rehabilitation intensity, transitional care models, and readmission-reduction interventions for patients discharged after major joint replacement or limb reattachment—particularly those with multiple chronic conditions who are at risk for functional decline or readmission. Typical endpoints include functional recovery trajectories, 30- to 90-day readmissions, post-acute facility utilization, and patient-reported outcomes, evaluated across different discharge destinations and care coordination models. This research is relevant to providers and payers because improvements in post-discharge management can decrease downstream utilization, improve functional outcomes, and influence total-cost-of-care metrics tied to bundled payments and DRG reimbursement models.

Local Excision and Removal of Internal Fixation Devices of Hip and Femur without CC/MCC: Inpatient Reimbursement Overview

501-SOFT-TISSUE-PROCEDURES-WITH-CC

Soft Tissue Procedures with CC: Inpatient Reimbursement Overview

518-BACK-AND-NECK-PROCEDURES-EXCEPT-SPINAL-FUSION-WITH-MCC-OR-DISC-DEVICE-OR-NEUROSTIMULATOR

Back and Neck Procedures Except Spinal Fusion with MCC or Disc Device or Neurostimulator: Inpatient Reimbursement Overview

552-MEDICAL-BACK-PROBLEMS-WITHOUT-MCC

Medical Back Problems without MCC: Inpatient Reimbursement Overview

534-FRACTURES-OF-FEMUR-WITHOUT-MCC

Fractures of Femur without MCC: Inpatient Reimbursement Overview

467-REVISION-OF-HIP-OR-KNEE-REPLACEMENT-WITH-CC

Revision of Hip or Knee Replacement with CC: Inpatient Reimbursement Overview

462-BILATERAL-OR-MULTIPLE-MAJOR-JOINT-PROCEDURES-OF-LOWER-EXTREMITY-WITHOUT-MCC

Bilateral or Multiple Major Joint Procedures of Lower Extremity without MCC: Inpatient Reimbursement Overview

447-MULTIPLE-LEVEL-SPINAL-FUSION-EXCEPT-CERVICAL-WITH-MCC-OR-CUSTOM-MADE-ANATOMICALLY-DESIGNED-INTERBODY-FUSION-DEVICE

Multiple Level Spinal Fusion Except Cervical with MCC: Inpatient Reimbursement Overview

498-LOCAL-EXCISION-AND-REMOVAL-OF-INTERNAL-FIXATION-DEVICES-OF-HIP-AND-FEMUR-WITH-CC-MCC

Local Excision and Removal of Internal Fixation Devices of Hip and Femur with CC/MCC: Inpatient Reimbursement Overview

456-SPINAL-FUSION-EXCEPT-CERVICAL-WITH-SPINAL-CURVATURE-MALIGNANCY-INFECTION-OR-EXTENSIVE-FUSIONS-WITH-MCC

Spinal Fusion Except Cervical with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 104

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Major Hip and Knee Joint Replacement or Reattachment: Inpatient Reimbursement Overview

DRG 469 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes